Definium Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert Barrow
- Full Time Employees
- 74
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- One World Trade Center New York NY United States of America 10007
- IPO Date
- Nov 15, 2016
- CIK
- 0001813814
- Website
- definiumtx.com
- Similar Companies
- Business
- Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing psychedelic-inspired therapeutics and brain-health medicines for psychiatric and neurodevelopmental disorders, including generalized anxiety disorder, autism spectrum disorder, and related conditions. Headquartered in New York, NY, the company operates primarily in the United States with a focus on late-stage clinical development and preparation for potential commercialization. Main Products and Services - Lead product candidates: DT120 (also referred to as DT120 ODT), an orally disintegrating tablet formulation in Phase 3 programs for generalized anxiety disorder (GAD) and major depressive disorder (MDD); MM120 (formerly MM-120), a lysergide D-tartrate derivative in development for generalized anxiety disorder and a subperceptual dosing approach for ADHD; DT402 (R-enantiomer of MDMA), studied in Phase 2a trials for autism spectrum disorder (ASD) core symptoms. - Early-stage pipeline: DT400-series programs and related compounds addressing brain health and mood disorders; preclinical and Phase 1/2 activities aimed at expanding therapeutic indications beyond anxiety and ASD. - Diagnostic and companion capabilities (where applicable): development programs aligned with precision psychiatry and patient stratification to optimize responder profiles and treatment regimens. - Clinical development services: design and execution of multi-center Phase 2/3 trials; regulatory strategy and interactions; data management, biostatistics, and pharmacovigilance for late-stage programs. - Pharmaceutical development enablement: formulation optimization, drug delivery science (including oral disintegrating tablets), and scaling considerations for potential commercialization. Latest Major Company Changes - Rebranding and strategic refocus: MindMed rebrands to Definium Therapeutics, signaling a shift toward a late-stage psychiatry pipeline and commitment to advancing three Phase 3 readouts in 2026, anchored by DT120 ODT for GAD and MDD, with a broader late-stage program footprint. - Pipeline advancement and late-stage emphasis: (>2026) Solidification of multiple Phase 3 trials in GAD and MDD, with additional Phase 3 readouts anticipated in 2026, reinforcing a strategy to prepare for potential commercialization and a best-in-class care model. - Ongoing expansion of late-stage and mid-stage assets: Continued progression of DT120 toward regulatory milestones, alongside the continuation of MM120 and DT402 programs, indicating an expanded portfolio and potential new indications or dosing paradigms. Industry context and business segments - Industry: Biopharmaceuticals with emphasis on psychiatric and neurological disorders, leveraging psychedelic-inspired therapeutics as a core strategic axis. - Business segments: Late-stage clinical development (Phase 3 programs for GAD and MDD), mid-stage and early-stage research (DT402 for ASD; MM120 for GAD/ADHD), and preparation for potential commercialization including operations and strategic partnerships. Geographic operations and corporate structure - Headquarters: New York, New York, United States; primary operating focus on U.S.-based clinical programs with regulatory interactions in major global markets. - Subsidiaries/affiliates: Corporate entity maintains oversight of global development programs, with potential regional partnerships or licensing discussions as part of a broader commercialization strategy, consistent with late-stage pharma company structures (as described in public disclosures). Founding year and corporate evolution - Founding background: Originally MindMed, established in 2010, transitions to Definium Therapeutics in 2026 as part of a strategic rebranding to emphasize a late-stage psychiatry pipeline; headquarters remain in the United States while pursuing global development objectives. Notes - The description reflects publicly disclosed information through early-2026 press releases and industry coverage, including rebranding announcements and Phase 3 program outlines; readers should consult the company’s investor relations materials for the most current clinical readouts and regulatory status. References indicate the rebranding and Phase 3-readout focus as central updates to the company’s profile in 2026.
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics Eyes Key DT-120 Depression Data, Advances Anxiety Program
Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics, Inc. (DFTX) Q1 2026 Earnings Call Transcript
Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Definium Therapeutics, Inc. (DFTX) Analyst/Investor Day Transcript
These 3 Psychedelic Stocks Activated After Trump's Executive Order
Trump Backs Psychedelics. Here's 1 Company Investors Need to Know About
Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day
FTSE 100 Live: London stocks slide as aerospace and defence sector falls
Definium Therapeutics (DFTX) Stock Gains After Hours: Here's What's Driving The Move
Definium Therapeutics Announces New Employee Inducement Grants
How Trump's psychedelics executive order could unlock stalled cannabis reform
Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar
Psychedelics stocks rise after Trump order expands research, access pathways
Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments
Definium: 'Strong Buy' Maintained On Several Anticipated 2026 Milestones
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events